GABPB2

Across TCGA pan-cancer cohorts, GABPB2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of GABPB2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where GABPB2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types GABPB2 is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

HNSC, LSCC, and COAD are the cancer types where GABPB2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GABPB2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	−0.332	.001	8	view →
LSCC	Female	All	−0.267	.018	4	view →
COAD	Female	All	−0.665	.049	3	view →
CCRCC	Male	All	+0.173	.002	3	view →
PDAC	Male	II,III,IV	−0.694	.009	2	view →
LUAD	All	All	−0.178	.011	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

GABPB2–HNSC

Open the HNSC breakdown →